Imidazo(4,3-b)(1,3)thiazole-7-carbaldehyde → 7-[[5-(Morpholin-4-yl)methylpyridin-3-yl]hydroxymethyl]imidazo[5,1-b]thiazole
反応式
Br[C:2]1[CH:3]=[C:4]([CH2:8][N:9]2[CH2:14][CH2:13][O:12][CH2:11][CH2:10]2)[CH:5]=[N:6][CH:7]=1.[CH:15]([C:17]1[N:18]=[CH:19][N:20]2[CH:24]=[CH:23][S:22][C:21]=12)=[O:16]>CCCCCC>[N:9]1([CH2:8][C:4]2[CH:3]=[C:2]([CH:15]([OH:16])[C:17]3[N:18]=[CH:19][N:20]4[CH:24]=[CH:23][S:22][C:21]=34)[CH:7]=[N:6][CH:5]=2)[CH2:14][CH2:13][O:12][CH2:11][CH2:10]1参加物
4
実験手順
7-[[5-(Morpholin-4-yl)methylpyridin-3-yl]hydroxymethyl]imidazo[5,1-b]thiazole (384 mg) was prepared in substantially the same manner as in step a) of Synthesis Example 5, except that 1.05 g of 4-(5-bromopyridin-3-yl)methylmorpholine, 2.70 ml of a 1.59 N nbutyllithium/n-hexane solution, and 426 mg of 7-formylimidazo[5,1-b]thiazole were used as the starting materials.